Claims
- 1. A method for treating an infection of a bacterium having a multiplying form and a non-multiplying form, said method comprising administering to a patient (i) a rifamycin antibiotic of formula (I); and (ii) an antibiotic effective against the multiplying form of said bacterium, wherein said rifamycin antibiotic is administered in an amount and for a duration sufficient to treat the non-multiplying form of said bacterium and the second antibiotic is administered in an amount and for a duration effective to treat said multiplying form of said bacterium.
- 2. The method of claim 1, wherein said antibiotic effective against said multiplying form of said bacterium is administered to said patient in an amount and for a duration to reduce the presence of said bacterium in said patient to less than about 106 organisms/mL; and said rifamycin antibiotic is then administered to said patient in an amount and for a duration effective to reduce the presence of said bacterium to or below a level indicative that said infection has been treated.
- 3. The method of claim 2, said method comprising the steps of:
(a) administering to said patient said antibiotic effective against said multiplying form of said bacterium for 1-7 days; and then (b) administering to said patient said rifamycin antibiotic for 1 to 15 days.
- 4. The method of claim 3, wherein step (a) consists of administering to said patient said antibiotic effective against said multiplying form of said bacterium for 1-3 days.
- 5. The method of claim 4, wherein step (b) comprises administering to said patient said rifamycin antibiotic for no more than 3 days.
- 6. The method of claim 1, wherein said rifamycin antibiotic is administered orally.
- 7. The method of claim 1, wherein said antibiotic effective against said multiplying form of said bacterium is administered intravenously.
- 8. The method of claim 1, wherein said antibiotic effective against said multiplying form of said bacterium is penicillin G, penicillin V, methicillin, oxacillin, cloxacillin, dicloxacillin, nafcillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, azlocillin, temocillin, cepalothin, cephapirn, cephradine, cephaloridine, cefazolin, cefamandole, cefuroxime, cephalexin, cefprozil, cefaclor, loracarbef, cefoxitin, cefmatozole, cefotaxime, ceftizoxime, ceftriaxone, cefoperazone, ceftazidime, cefixime, cefpodoxime, ceftibuten, cefdinir, cefpirome, cefepime, BAL5788, BAL9141, imipenem, ertapenem, meropenem, astreonam, clavulanate, sulbactam, tazobactam, streptomycin, neomycin, kanamycin, paromycin, gentamicin, tobramycin, amikacin, netilmicin, spectinomycin, sisomicin, dibekalin, isepamicin, tetracycline, chlortetracycline, demeclocycline, minocycline, oxytetracycline, methacycline, doxycycline, erythromycin, azithromycin, clarithromycin, telithromycin, ABT-773, lincomycin, clindamycin, vancomycin, oritavancin, dalbavancin, teicoplanin, quinupristin and dalfopristin, sulphanilamide, para-aminobenzoic acid, sulfadiazine, sulfisoxazole, sulfamethoxazole, sulfathalidine, linezolid, nalidixic acid, oxolinic acid, norfloxacin, perfloxacin, enoxacin, ofloxacin, ciprofloxacin, temafloxacin, lomefloxacin, fleroxacin, grepafloxacin, sparfloxacin, trovafloxacin, clinafloxacin, gatifloxacin, moxifloxacin, gemifloxacin, sitafloxacin, metronidazole, daptomycin, garenoxacin, ramoplanin, faropenem, polymyxin, tigecycline, AZD2563, or trimethoprim.
- 9. The method of claim 1, wherein said rifamycin antibiotic is rifalazil.
- 10. The method of claim 9, wherein said rifalazil is administered orally.
- 11. The method of claim 9, wherein said rifalazil is administered intravenously.
- 12. The method of claim 1, wherein said bacterium is of the species Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Enterococcus faecium, Clostridium perfringens, Streptococcus pyogenes, or Streptococcus pneumoniae.
- 13. A method of eradicating non-multiplying bacteria not eradicated in a patient following treatment with a first antibiotic, said method comprising administering to said patient a rifamycin antibiotic of formula (I) in an amount and for a duration sufficient to eradicate said non-multiplying bacteria in said patient.
- 14. The method of claim 13, wherein said rifamycin antibiotic is administered orally.
- 15. The method of claim 13, wherein said rifamycin antibiotic is rifalazil.
- 16. The method of claim 15, wherein said rifalazil is administered orally.
- 17. The method of claim 15, wherein said rifalazil is administered intravenously.
- 18. The method of claim 13, wherein said bacterium is of the species Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Enterococcus faecium, Clostridium perfringens, Streptococcus pyogenes, or Streptococcus pneumoniae.
- 19. A pharmaceutical composition comprising (i) a rifamycin antibiotic of formula (I) and a second antibiotic selected from penicillin G, penicillin V, methicillin, oxacillin, cloxacillin, dicloxacillin, nafcillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, meziocillin, piperacillin, azlocillin, temocillin, cepalothin, cephapirin, cephradine, cephaloridine, cefazolin, cefamandole, cefuroxime, cephalexin, cefprozil, cefaclor, loracarbef, cefoxitin, cefmatozole, cefotaxime, ceftizoxime, ceftriaxone, cefoperazone, ceftazidime, cefixime, cefpodoxime, ceftibuten, cefdinir, cefpirome, cefepime, BAL5788, BAL9141, imipenem, ertapenem, meropenem, astreonam, clavulanate, sulbactam, tazobactam, streptomycin, neomycin, kanamycin, paromycin, gentamicin, tobramycin, amikacin, netilmicin, spectinomycin, sisomicin, dibekalin, isepamicin, tetracycline, chlortetracycline, demeclocycline, minocycline, oxytetracycline, methacycline, doxycycline, erythromycin, azithromycin, clarithromycin, telithromycin, ABT-773, lincomycin, clindamycin, vancomycin, oritavancin, dalbavancin, teicoplanin, quinupristin and dalfopristin, sulphanilamide, para-aminobenzoic acid, sulfadiazine, sulfisoxazole, sulfamethoxazole, sulfathalidine, linezolid, nalidixic acid, oxolinic acid, norfloxacin, perfloxacin, enoxacin, ofloxacin, ciprofloxacin, temafloxacin, lomefloxacin, fleroxacin, grepafloxacin, sparfloxacin, trovafloxacin, clinafloxacin, gatifloxacin, moxifloxacin, gemifloxacin, sitafloxacin, metronidazole, daptomycin, garenoxacin, ramoplanin, faropenem, polymyxin, tigecycline, AZD2563, and trimethoprim.
- 20. The composition of claim 17, wherein said rifamycin antibiotic is rifalazil.
- 21. A method of treating a patient diagnosed as having a chronic disease associated with a bacterial infection caused by bacteria capable of establishing a non-multiplying form phase, said method comprising the step of administering to said patient a rifamycin antibiotic of formula (I), wherein said administering is for a duration and in an amount effective to treat said patient.
- 22. The method of claim 21, wherein said chronic disease is an inflammatory disease.
- 23. The method of claim 22, wherein said inflammatory disease is selected from the group consisting of asthma, coronary artery disease, arthritis, conjunctivitis, lymphogranuloma venerum, cervicitis, and salpingitis.
- 24. The method of claim 21, wherein said chronic disease is an autoimmune disease.
- 25. The method of claim 24, wherein said autoimmune disease is selected from the group consisting of systemic lupus erythematosus, diabetes mellitus, and graft versus host disease.
- 26. The method of claim 21, wherein said chronic disease is atherosclerosis.
- 27. The method of claim 21, wherein said rifamycin antibiotic is rifalazil.
- 28. A method of treating the cryptic phase of a bacterial infection, said method comprising the step of administering to a patient a rifamycin antibiotic of formula (I), wherein said administering is for a duration and in an amount effective to treat said cryptic phase of said bacterial infection.
- 29. The method of claim 28, wherein said rifamycin antibiotic is rifalazil.
- 30. The method of claim 28, wherein said bacterial infection is caused by C. trachomatis, C. pneumoniae, C. psittaci, C. suis, C. pecorum, C. abortus, C. caviae, C. felis, C. muridarum, N. hartmannellae, W. chondrophila, S. negevensis, or P. acanthamoeba.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. Provisional Application No. 60/382,805, filed May 23, 2002, which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60382805 |
May 2002 |
US |